Pancreatic Cancer Research

ResearcherShenzhen UniversityActive in the last 2 years

Peng Gong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3018-6104; OpenAlex author ID A5101920890. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 3

  1. A novel BCAT1 inhibitor bufalin sensitizes pancreatic cancer cells to chemotherapy. Last author DOI 10.1016/j.gendis.2024.101503↗
  2. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation. Co-author DOI 10.1016/j.canlet.2024.216733↗
  3. Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. Co-author DOI 10.7150/jca.33029↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianbin Zhang · 3 shared papers, 2020–2025 · strength 0.57
  2. Milad Ashrafizadeh · 2 shared papers, 2024–2025 · strength 0.45
  3. Wei Zhang · 1 shared paper, 2025 · strength 0.25
  4. Pingping Zhang · 1 shared paper, 2024 · strength 0.21
  5. Jiahui Yuan · 1 shared paper, 2024 · strength 0.21
  6. Dietmar Zechner · 1 shared paper, 2020 · strength 0.12
  7. Brigitte Vollmar · 1 shared paper, 2020 · strength 0.12
  8. Simone Kumstel · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.